Replies to post #441395 on NorthWest Biotherapeutics Inc (NWBO)

[Hbpainter]

Not forgetting hyperprogression which Longfellow found a great deal of information about.

[jondoeuk]

GILD's Yescarta DLBCL anti-CD-19 CAR-T efficacy;

3rd line label (so approved): 51% CR; 72% ORR; 43% alive at Year 5 (64% for CR's); 92% of them had no further treatments.

2nd line: 65% CR; 83% ORR; PDUFA is on April 1st (2H in the EU).

1st line: 78% CR; 89% ORR.

So imagine what happens if earlier line patients don't relapse at the same rate as the current label. That changes the game, and not just from an insurance perspective.

As for SAEs, they are far better managed than they once were, with additional therapies in development that could stop them altogether https://www.businesswire.com/news/home/20210419005250/en/Humanigen-Reports-Positive-Data-With-Lenzilumab-in-the-ZUMA-19-CAR-T-Phase-1b-Study-in-DLBCL-and-Plans-to-Initiate-a-Potential-Registrational-Study